JP5653215B2 - Ｇａｓ５７変異体抗原およびｇａｓ５７抗体 - Google Patents

Ｇａｓ５７変異体抗原およびｇａｓ５７抗体 Download PDF

Info

Publication number
JP5653215B2
JP5653215B2 JP2010524598A JP2010524598A JP5653215B2 JP 5653215 B2 JP5653215 B2 JP 5653215B2 JP 2010524598 A JP2010524598 A JP 2010524598A JP 2010524598 A JP2010524598 A JP 2010524598A JP 5653215 B2 JP5653215 B2 JP 5653215B2
Authority
JP
Japan
Prior art keywords
antigen
gas57
amino acid
antigens
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010524598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538634A (ja
JP2010538634A5 (cg-RX-API-DMAC7.html
Inventor
ワイ ロス， イマクラーダ マーガリト
ワイ ロス， イマクラーダ マーガリト
グランディ，　グイド
グイド グランディ，
チアラ ジンガレッティ，
チアラ ジンガレッティ，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010538634A publication Critical patent/JP2010538634A/ja
Publication of JP2010538634A5 publication Critical patent/JP2010538634A5/ja
Application granted granted Critical
Publication of JP5653215B2 publication Critical patent/JP5653215B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2010524598A 2007-09-12 2008-09-12 Ｇａｓ５７変異体抗原およびｇａｓ５７抗体 Expired - Fee Related JP5653215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97163707P 2007-09-12 2007-09-12
US60/971,637 2007-09-12
PCT/IB2008/003078 WO2009034473A2 (en) 2007-09-12 2008-09-12 Gas57 mutant antigens and gas57 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014179867A Division JP2014230547A (ja) 2007-09-12 2014-09-04 Ｇａｓ５７変異体抗原およびｇａｓ５７抗体

Publications (3)

Publication Number Publication Date
JP2010538634A JP2010538634A (ja) 2010-12-16
JP2010538634A5 JP2010538634A5 (cg-RX-API-DMAC7.html) 2011-10-13
JP5653215B2 true JP5653215B2 (ja) 2015-01-14

Family

ID=40403336

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010524598A Expired - Fee Related JP5653215B2 (ja) 2007-09-12 2008-09-12 Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
JP2014179867A Withdrawn JP2014230547A (ja) 2007-09-12 2014-09-04 Ｇａｓ５７変異体抗原およびｇａｓ５７抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014179867A Withdrawn JP2014230547A (ja) 2007-09-12 2014-09-04 Ｇａｓ５７変異体抗原およびｇａｓ５７抗体

Country Status (12)

Country Link
US (5) US8287885B2 (cg-RX-API-DMAC7.html)
EP (1) EP2197485B1 (cg-RX-API-DMAC7.html)
JP (2) JP5653215B2 (cg-RX-API-DMAC7.html)
KR (1) KR101621837B1 (cg-RX-API-DMAC7.html)
CN (1) CN101969992B (cg-RX-API-DMAC7.html)
AU (1) AU2008299376B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816689B1 (cg-RX-API-DMAC7.html)
CA (1) CA2699513C (cg-RX-API-DMAC7.html)
ES (1) ES2561483T3 (cg-RX-API-DMAC7.html)
MX (1) MX2010002773A (cg-RX-API-DMAC7.html)
RU (2) RU2471497C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009034473A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1328543B1 (en) * 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
JP5653215B2 (ja) * 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
SI2344523T1 (sl) * 2008-09-17 2016-06-30 Glaxosmithkline Biologicals S.A. Kombinirana GAS-cepiva in zdravila
CA2945052C (en) * 2014-04-15 2023-05-02 Griffith University Group a streptococcus vaccine
AU2016248452B2 (en) 2015-04-16 2018-05-31 Inventprise, Inc. Bordetella pertussis immunogenic vaccine compositions
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN114921418B (zh) * 2022-06-23 2023-08-18 金河佑本生物制品有限公司 一株o型口蹄疫类病毒颗粒单克隆抗体的杂交瘤细胞株1d3及试剂盒和检测方法
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
EP0251575B2 (en) 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5098827A (en) 1988-02-26 1992-03-24 The University Of Florida Novel bacterial markers for pathogenic group B streptococci
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5354846A (en) 1988-11-18 1994-10-11 Michael Kehoe Streptolysin O antigen derivatives, its production and uses
GB8827038D0 (en) 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
DE68929323T2 (de) 1988-12-16 2002-04-18 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
GB2233977B (en) 1989-01-04 1993-03-31 Michael Kehoe Cytolytic streptolysin o mutants and uses
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US6737521B1 (en) 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
US5821088A (en) 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69228247T2 (de) 1991-08-10 1999-07-08 Medical Research Council, London Behandlung von Zellpopulationen
US5391712A (en) 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5378620A (en) 1991-08-30 1995-01-03 Beckman Instruments, Inc. Streptolysin O derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
JP3368902B2 (ja) 1992-03-02 2003-01-20 カイロン エセ．ピー．アー． ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE4240056A1 (de) 1992-11-28 1994-06-01 Boehringer Mannheim Gmbh Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
PT613947E (pt) 1993-02-01 2004-07-30 Beckman Coulter Inc Factor mitogenico seu gene e metodo para a sua microdeteccao
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
DE69433107T2 (de) 1993-06-23 2004-07-08 Beckman Coulter, Inc., Fullerton Rekombinante dnase b aus streptococcus pyogenes
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT804559E (pt) 1994-10-07 2005-08-31 Univ Rockefeller Enzima para clivagem da regiao ancora de proteinas de superficie de bacterias gram-positivas
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
WO1997037026A1 (en) 1996-04-02 1997-10-09 Smithkline Beecham Corporation Novel compounds
US6346392B1 (en) 1996-11-27 2002-02-12 Smithkline Beecham Corporation Polynucleotides encoding a novel glutamine transport ATP-binding protein
EP0914330A4 (en) 1996-05-14 2002-01-09 Smithkline Beecham Corp NEW TYPE COMPOUNDS
IES76925B2 (en) 1996-07-03 1997-11-19 Provost Subunit Vaccine for Streptococcus Equi
EP0821070A1 (en) 1996-07-22 1998-01-28 Carelli, Claude Marcel Henri Pit-1 gene polymorphism and trait selection in animals
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
CA2264496C (en) 1996-09-04 2008-10-07 Takara Shuzo Co., Ltd. Fungal antigens and process for producing the same
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
WO1998019689A1 (en) 1996-11-01 1998-05-14 Smithkline Beecham Corporation Novel coding sequences
EP0966304B1 (en) 1997-02-20 2005-05-25 David S. Dime Site-specific drug delivery
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
KR20010012236A (ko) 1997-05-06 2001-02-15 벤슨 로버트 에이치. 엔테로코쿠스 파에칼리스 폴리뉴클레오티드 및 폴리펩티드
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
WO1999006951A1 (en) 1997-07-31 1999-02-11 Intergraph Corporation Alignment and distribution apparatus and method
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
EP1003875B1 (en) 1997-09-12 2006-12-27 University of Tennessee Research Foundation Group a streptococcal vaccines
US6406883B1 (en) 1997-09-26 2002-06-18 Luetticken Rudolf Lmb gene of Streptococcus agalactiae
EP1037997A1 (en) 1997-09-26 2000-09-27 Medimmune, Inc. Lmb gene of streptococcus agalactiae
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
BR9813071A (pt) 1997-10-17 2000-08-15 Nestle Sa Espécie de bactéria láctica
EP2278006A3 (en) 1997-11-06 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
CA2307846A1 (en) 1997-11-21 1999-06-03 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO1999026969A1 (en) 1997-11-21 1999-06-03 University Of Otago Zoocin a immunity factor
EP2228384A1 (en) 1997-11-28 2010-09-15 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
WO1999035270A1 (en) 1997-12-31 1999-07-15 Stressgen Biotechnologies Corporation Streptococcal heat shock proteins of the hsp60 family
DK1047784T4 (en) 1998-01-14 2015-06-15 Novartis Vaccines & Diagnostic NEISSERA meningitidis ANTIGENS
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
ID27482A (id) 1998-02-20 2001-04-12 Iaf Biochem Int Antigen streptococcus kelompok b
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
GB9808327D0 (en) 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
US6660520B2 (en) 1998-06-05 2003-12-09 Smithkline Beecham Corporation Nrde
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
CA2337102A1 (en) 1998-07-27 2000-02-10 Richard William Falla Le Page Nucleic acids and proteins from group b streptococcus
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
US6936252B2 (en) 1998-07-27 2005-08-30 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
WO2000006737A2 (en) 1998-07-27 2000-02-10 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
AU784043B2 (en) 1999-04-15 2006-01-19 Regents Of The University Of California, The Identification of sortase gene
US7101692B2 (en) 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
WO2000067161A2 (en) 1999-05-04 2000-11-09 Grant Lee H Method and apparatus for categorizing and retrieving network pages and sites
WO2000078787A1 (en) 1999-06-21 2000-12-28 University Of Utah Research Foundation ISOLATED GENES FROM VIRULENT GROUP B $i(STREPTOCOCCUS AGALACTIAE)
US6833356B1 (en) 1999-08-25 2004-12-21 Medimmune, Inc. Pneumococcal protein homologs and fragments for vaccines
GB9921125D0 (en) 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
EP1265582A2 (en) 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
WO2001070955A2 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AU2001272497A1 (en) 2000-06-23 2002-01-02 Bayer Aktiengesellschaft Regulation of human mast cell protease 6-like enzyme
AU2001276619A1 (en) 2000-07-03 2002-01-14 Chiron S.P.A. Immunisation against chlamydia pneumoniae
JP4718099B2 (ja) 2000-07-06 2011-07-06 アイディー バイオメディカル コーポレイション ストレプトコッカス・パイオジェンス抗原
DE60128115T2 (de) 2000-08-08 2008-03-06 St. Jude Children's Research Hospital, Memphis Gruppe-b streptococcus polypeptide, nukleinsäure, therapeutische zusammensetzungen und impfstoffe davon
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
US7160547B2 (en) 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
WO2002057315A2 (en) 2000-10-10 2002-07-25 University Of Tennessee Research Corporation Streptococcal streptolysin s vaccines
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
EP2316482A1 (en) 2001-03-19 2011-05-04 Intercell USA, Inc. Transcutaneous immunostimulation
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US20070128229A1 (en) 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
EP1421098A4 (en) 2001-04-13 2006-03-15 Wyeth Corp SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES
FR2824074A1 (fr) 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
EP1399181B1 (en) 2001-05-18 2012-05-09 The Government of the USA, as represented by the Secretary, Dept. of Health and Human Services, Centers for Disease Control and Prevention Peptide vaccines against group a streptococci
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20060073530A1 (en) 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
KR100982204B1 (ko) 2001-12-12 2010-09-14 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 클라미디아 트라코마티스에 대한 면역화
WO2003068813A2 (en) 2002-02-11 2003-08-21 Shire Biochem Inc Group b streptococcus antigen
GB2385274B (en) 2002-02-13 2004-04-14 Ming-Jeng Shue Vaginal suppository delivery device
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
WO2003087353A2 (en) 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
US20050181388A1 (en) 2002-04-02 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
AU2003260102A1 (en) 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
ES2504166T3 (es) 2002-09-13 2014-10-08 Novartis Vaccines And Diagnostics, Inc. Vacuna de estreptococo del grupo B
TW566366U (en) 2002-09-27 2003-12-11 Wus Tech Co Ltd Labor-saving portable battery equipment for power-driven walking assisted scooter
CN1705679B (zh) 2002-10-15 2011-04-06 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
CA2517518A1 (en) 2003-03-04 2004-09-16 Intercell Ag Streptococcus pyogenes antigens
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
RU2352356C2 (ru) 2003-06-26 2009-04-20 Новартис Вэксинес Энд Дайэгностикс, Инк. ИММУНОГЕННАЯ КОМПОЗИЦИЯ НА ОСНОВЕ АНТИГЕНА Chlamydia trachomatis (ВАРИАНТЫ) И ЕЕ ИСПОЛЬЗОВАНИЕ
JP4875490B2 (ja) * 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
AU2003904237A0 (en) 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
WO2005028618A2 (en) 2003-09-15 2005-03-31 Chiron Corporation Immunogenic compositions for streptococcus agalactiae
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
WO2005076010A2 (en) 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0421465D0 (en) 2004-09-27 2004-10-27 Chiron Srl Group A streptococcus protein
AU2005335216A1 (en) 2004-10-05 2007-02-15 Wyeth Probe arrays for detecting multiple strains of different species
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2006069200A2 (en) 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
JP5219803B2 (ja) 2005-05-13 2013-06-26 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド グラム陽性菌の血清耐性因子
EP1770171A1 (en) 2005-09-29 2007-04-04 Universität Zu Köln DNA microarray for rapid identification of Candida albicans in blood cultures.
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
EP2287189A1 (en) * 2006-07-07 2011-02-23 Intercell AG Small Streptococcus pyogenes antigens and their use
JP2010508276A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 化膿連鎖球菌のための免疫原性組成物および治療組成物
JP5653215B2 (ja) * 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体

Also Published As

Publication number Publication date
KR101621837B1 (ko) 2016-05-17
RU2471497C2 (ru) 2013-01-10
CA2699513A1 (en) 2009-03-19
BRPI0816689A2 (pt) 2017-06-13
US20130202609A1 (en) 2013-08-08
RU2012142305A (ru) 2014-04-10
WO2009034473A3 (en) 2009-05-14
CN101969992A (zh) 2011-02-09
US9102741B2 (en) 2015-08-11
ES2561483T3 (es) 2016-02-26
CA2699513C (en) 2018-03-13
AU2008299376A1 (en) 2009-03-19
JP2010538634A (ja) 2010-12-16
CN101969992B (zh) 2014-10-01
US20160137702A1 (en) 2016-05-19
US8858957B2 (en) 2014-10-14
KR20100075898A (ko) 2010-07-05
US20110110967A1 (en) 2011-05-12
US20150030625A1 (en) 2015-01-29
EP2197485A2 (en) 2010-06-23
MX2010002773A (es) 2010-03-31
US8399651B2 (en) 2013-03-19
US20130005030A1 (en) 2013-01-03
BRPI0816689B1 (pt) 2021-08-24
US8287885B2 (en) 2012-10-16
EP2197485B1 (en) 2015-11-11
WO2009034473A2 (en) 2009-03-19
AU2008299376B2 (en) 2013-02-28
JP2014230547A (ja) 2014-12-11
RU2010113896A (ru) 2011-10-20

Similar Documents

Publication Publication Date Title
JP5656642B2 (ja) ストレプトリシンｏの変異体形態
JP5680536B2 (ja) 組み合わせｇａｓワクチンおよび治療法
JP2014230547A (ja) Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
JP2010538634A5 (cg-RX-API-DMAC7.html)
AU2013203022B2 (en) GAS57 mutant antigens and GAS57 antibodies
AU2013203063A1 (en) Combination gas vaccines and therapeutics

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140904

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141118

R150 Certificate of patent or registration of utility model

Ref document number: 5653215

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees